We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment

WHO recommends two new drugs for COVID-19

Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation

Evonik to build production plant for rhamnolipids in Slovakia

The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years

Metropolis Healthcare opens MedEngage Scholarship programme

The last date to apply for this program is 18th January 2022

Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021

This surpasses the number of approvals supported in 2020

Merck KGaA to acquire biopharma CDMO Exelead for $780 million

The transaction is expected to close in the first quarter of 2022

Covaxin receives approval for Emergency Use in Children 12-18 years

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000

World Health Organisation SAGE recommends use of Novavax Covid-19 vaccine as booster

SAGE recommends additional third dose of the vaccine administered to immunocompromised persons

Six benefits of Cloud Computing in the pharma industry